Suchen
Kodiak Sciences Inc
KODZur Watchlist hinzufügen
41.580USD
-0.920-2.16%
Handelsschluss 07-31 16:00（ET）Kurse um 15 Minuten verzögert
2.60BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Kodiak Sciences Inc Unternehmen
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Kodiak Sciences Inc Informationen
BörsenkürzelKOD
Name des UnternehmensKodiak Sciences Inc
IPO-datumOct 04, 2018
CEOPerlroth (Victor)
Anzahl der mitarbeiter109
WertpapierartOrdinary Share
GeschäftsjahresendeOct 04
Addresse1250 Page Mill Rd
StadtPALO ALTO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94304
Telefon16502810850
Websitehttps://kodiak.com/
BörsenkürzelKOD
IPO-datumOct 04, 2018
CEOPerlroth (Victor)
Führungskräfte von Kodiak Sciences Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
211.93K
--
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
Independent Director
Independent Director
--
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
211.93K
--
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Kodiak Sciences Inc?
Die fünf größten Anteilseigner von Kodiak Sciences Inc sind: Mr. John A. Borgeson
Wie viele Institutionen halten Anteile an Kodiak Sciences Inc (KOD)?
Mit Stand vom 2026Q1 halten 311 Institutionen Anteile an Kodiak Sciences Inc, mit einem Gesamtmarktwert von etwa 60.04M, was 96.04% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 7956993.00 gestiegen.